Remarkably even, the relatively weak binding VHH-2 proved to be among the most capable CAR-T cell activating VHHs, while – in line with its affinity for CS1 -, MM cell binding and in vivo MM tumor tracing capacity are inferior. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.